2025 Q2 -tulosraportti
219 päivää sitten
‧37 min
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2025 Q4 -tulosraportti 15.4. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 | ||
2023 Q3 -tulosraportti 9.11.2023 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·13 t sittenIs written very differently. I think the different dates are essential in relation to the price and people's retention for the next months. - I also think things look good, but it's best if people are also just honest and stick to the facts.
·10 min sittenThis is a stock with a good foundation after several years of research. But that they have managed to build a platform out of it all is simply to take one's hat off to them. This is a future investment for those who have paid attention. We are entering a new phase where Circio is suddenly a leading player in a market that is red-hot right now. Good luck to all who choose to follow them on the journey… Amen..
14 t sitten14 t sitten☺️
·10 t sittenIf the investment goes well, then it's certainly allowed to dream.
·2 t sittenSo, it will probably be about creating a good dividend portfolio.
·16 t sittenRetrieved from tekinvestor : https://www.ad-hoc-news.de/boerse/news/ueberblick/circio-holding-aktie-meilensteine-voraus/69069087 The Germans are coming, they see that Crna is barely in its starting blocks, so some Norwegians might think it has already gone far, I believe in an exciting journey from here with increased interest far beyond our borders.·13 t sittenThe most important thing about the article are these 3 lines: Scientific recognition at the ASGCT conference provides Circio with a global platform. The data presented there and the resulting interest from potential licensees, along with the financial reach, are key factors for further development
·1 päivä sittenWill the share price fall due to dilution upon exercise of Warrants? Answer: NO!! Explanation: Given a VWAP price of kr 11, the exercise price (Strike) becomes kr 8.8. If the CRNA share price remains at 11 until exercise, one must expect that between 70-95% of the warrants will be exercised; if the price rises after the strike is set, the exercise rates increase to between 90-100%. So, 1 new share is issued per exercised warrant, and this means a 50% dilution if 100% of warrants are exercised. BUT it also means that CRNA will be infused with a value of between 412-590 million kroner!!, i.e., up to 12x the last emission (approx. 50 million kr). And that without broker fees, discounted issues, etc. This means that CRNA will be secured for operations for a long time to come, the ghost of emission disappears, and the negotiating position towards big pharma becomes significantly better. In summary, the value of CRNA is significantly increased and risks are greatly reduced, which will lead to an increased share price after the dilution!
·1 päivä sittenOpen Article from investornytt "Is Circio the Next Billion-Dollar Acquisition?" https://www.investornytt.no/nyheter/er-circio-neste-milliardoppkjop/522255 «Wiklund acknowledges that the company could be an acquisition target if the development continues in the same direction.» And; https://www.investornytt.no/nyheter/biotek-aksje-med-50x-effekt/522160
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q2 -tulosraportti
219 päivää sitten
‧37 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·13 t sittenIs written very differently. I think the different dates are essential in relation to the price and people's retention for the next months. - I also think things look good, but it's best if people are also just honest and stick to the facts.·10 min sittenThis is a stock with a good foundation after several years of research. But that they have managed to build a platform out of it all is simply to take one's hat off to them. This is a future investment for those who have paid attention. We are entering a new phase where Circio is suddenly a leading player in a market that is red-hot right now. Good luck to all who choose to follow them on the journey… Amen..
- 14 t sitten14 t sitten☺️·10 t sittenIf the investment goes well, then it's certainly allowed to dream.·2 t sittenSo, it will probably be about creating a good dividend portfolio.
- ·16 t sittenRetrieved from tekinvestor : https://www.ad-hoc-news.de/boerse/news/ueberblick/circio-holding-aktie-meilensteine-voraus/69069087 The Germans are coming, they see that Crna is barely in its starting blocks, so some Norwegians might think it has already gone far, I believe in an exciting journey from here with increased interest far beyond our borders.·13 t sittenThe most important thing about the article are these 3 lines: Scientific recognition at the ASGCT conference provides Circio with a global platform. The data presented there and the resulting interest from potential licensees, along with the financial reach, are key factors for further development
- ·1 päivä sittenWill the share price fall due to dilution upon exercise of Warrants? Answer: NO!! Explanation: Given a VWAP price of kr 11, the exercise price (Strike) becomes kr 8.8. If the CRNA share price remains at 11 until exercise, one must expect that between 70-95% of the warrants will be exercised; if the price rises after the strike is set, the exercise rates increase to between 90-100%. So, 1 new share is issued per exercised warrant, and this means a 50% dilution if 100% of warrants are exercised. BUT it also means that CRNA will be infused with a value of between 412-590 million kroner!!, i.e., up to 12x the last emission (approx. 50 million kr). And that without broker fees, discounted issues, etc. This means that CRNA will be secured for operations for a long time to come, the ghost of emission disappears, and the negotiating position towards big pharma becomes significantly better. In summary, the value of CRNA is significantly increased and risks are greatly reduced, which will lead to an increased share price after the dilution!
- ·1 päivä sittenOpen Article from investornytt "Is Circio the Next Billion-Dollar Acquisition?" https://www.investornytt.no/nyheter/er-circio-neste-milliardoppkjop/522255 «Wiklund acknowledges that the company could be an acquisition target if the development continues in the same direction.» And; https://www.investornytt.no/nyheter/biotek-aksje-med-50x-effekt/522160
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2025 Q4 -tulosraportti 15.4. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 | ||
2023 Q3 -tulosraportti 9.11.2023 |
2025 Q2 -tulosraportti
219 päivää sitten
‧37 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2025 Q4 -tulosraportti 15.4. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 | ||
2023 Q3 -tulosraportti 9.11.2023 |
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·13 t sittenIs written very differently. I think the different dates are essential in relation to the price and people's retention for the next months. - I also think things look good, but it's best if people are also just honest and stick to the facts.·10 min sittenThis is a stock with a good foundation after several years of research. But that they have managed to build a platform out of it all is simply to take one's hat off to them. This is a future investment for those who have paid attention. We are entering a new phase where Circio is suddenly a leading player in a market that is red-hot right now. Good luck to all who choose to follow them on the journey… Amen..
- 14 t sitten14 t sitten☺️·10 t sittenIf the investment goes well, then it's certainly allowed to dream.·2 t sittenSo, it will probably be about creating a good dividend portfolio.
- ·16 t sittenRetrieved from tekinvestor : https://www.ad-hoc-news.de/boerse/news/ueberblick/circio-holding-aktie-meilensteine-voraus/69069087 The Germans are coming, they see that Crna is barely in its starting blocks, so some Norwegians might think it has already gone far, I believe in an exciting journey from here with increased interest far beyond our borders.·13 t sittenThe most important thing about the article are these 3 lines: Scientific recognition at the ASGCT conference provides Circio with a global platform. The data presented there and the resulting interest from potential licensees, along with the financial reach, are key factors for further development
- ·1 päivä sittenWill the share price fall due to dilution upon exercise of Warrants? Answer: NO!! Explanation: Given a VWAP price of kr 11, the exercise price (Strike) becomes kr 8.8. If the CRNA share price remains at 11 until exercise, one must expect that between 70-95% of the warrants will be exercised; if the price rises after the strike is set, the exercise rates increase to between 90-100%. So, 1 new share is issued per exercised warrant, and this means a 50% dilution if 100% of warrants are exercised. BUT it also means that CRNA will be infused with a value of between 412-590 million kroner!!, i.e., up to 12x the last emission (approx. 50 million kr). And that without broker fees, discounted issues, etc. This means that CRNA will be secured for operations for a long time to come, the ghost of emission disappears, and the negotiating position towards big pharma becomes significantly better. In summary, the value of CRNA is significantly increased and risks are greatly reduced, which will lead to an increased share price after the dilution!
- ·1 päivä sittenOpen Article from investornytt "Is Circio the Next Billion-Dollar Acquisition?" https://www.investornytt.no/nyheter/er-circio-neste-milliardoppkjop/522255 «Wiklund acknowledges that the company could be an acquisition target if the development continues in the same direction.» And; https://www.investornytt.no/nyheter/biotek-aksje-med-50x-effekt/522160
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Välittäjätilasto
Dataa ei löytynyt